Engineered immune cells take on tough leukemia in early trial
NCT ID NCT07336875
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of cell therapy called CAR-ITNK cells, designed to target two proteins (CD70 and CLL1) on leukemia cells. It will enroll 30 adults with relapsed or refractory acute myeloid leukemia (AML) who have not responded to standard treatments. Participants receive a single infusion of these engineered cells after chemotherapy to prepare the body, and are followed for three years to check safety and how well the leukemia responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-ITNK cells targeting CD70 and CLL1
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia that has not responded to standard therapies.
- What could go wrong
- This is a very early, small trial (30 people) focused on safety, so it may not lead to an effective treatment. Cell therapies can cause severe side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.